<DOC>
	<DOC>NCT01316276</DOC>
	<brief_summary>The purpose of this study is to evaluate the long term safety and tolerability of Arikayce in Cystic Fibrosis patients. This long-term, open-label, multi-cycle extension study will enroll subjects who have successfully completed study TR02-108, were compliant with the study protocol, and did not meet any of the listed study discontinuation criteria. The safety and tolerability of Arikayce will be evaluated for up to approximately 2 years.</brief_summary>
	<brief_title>Extension Study of Arikayce in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Key Written informed consent or assent Subject has completed study TR02108, and has been compliant with the study protocol Women of childbearing potential must agree to use reliable methods of contraception for the duration of the study Key Subject met any of the listed criteria for study drug discontinuation in protocol TR02108. Abnormal laboratory assessments including LFT (≥ 3× ULN), serum creatinine (&gt; 2× ULN) and ANC (&lt; 1000). Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements. History of alcohol, medication or illicit drug abuse within the 6 months prior to consent. Smoking tobacco or any substance within 6 months prior to consent or anticipated inability to refrain from smoking throughout the study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Respiratory Infections</keyword>
	<keyword>Pulmonary Cystic Fibrosis</keyword>
	<keyword>CFTR</keyword>
	<keyword>Anti-bacterial Agent</keyword>
</DOC>